Article info

Download PDFPDF

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis

Authors

  1. Correspondence to Prof Elsa Vieira-Sousa, Universidade de Lisboa Instituto de Medicina Molecular, Lisboa 1649-028, Portugal; elsa-sousa{at}hotmail.com
View Full Text

Citation

Vieira-Sousa E, Alves P, Rodrigues AM, et al
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis

Publication history

  • Received October 18, 2019
  • Revised February 1, 2020
  • Accepted February 3, 2020
  • First published March 19, 2020.
Online issue publication 
March 19, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.